Journal
CELLULAR & MOLECULAR IMMUNOLOGY
Volume 10, Issue 4, Pages 303-310Publisher
CHIN SOCIETY IMMUNOLOGY
DOI: 10.1038/cmi.2012.69
Keywords
triple negative breast cancer; CCL5; myeloid derived suppressor cell; immunotherapy
Categories
Funding
- Susan G. Komen Breast Cancer Foundation [KG091243]
Ask authors/readers for more resources
Breast cancer (BC) is a leading cause of mortality among women in the world. To date, a number of molecules have been established as disease status indicators and therapeutic targets. The best known among them are estrogen receptor-alpha (ER-alpha), progesterone receptor (PR) and HER-2/neu. About 15%-20% BC patients do not respond effectively to therapies targeting these classes of tumor-promoting factors. Thus, additional targets are strongly and urgently sought after in therapy for human BCs negative for ER, PR and HER-2, the so-called triple-negative BC (TNBC). Recent clinical work has revealed that CC chemokine ligand 5 (CCL5) is strongly associated with the progression of BC, particularly TNBC. How CCL5 contributes to the development of TNBC is not well understood. Experimental animal studies have begun to address the mechanistic issue. In this article, we will review the clinical and laboratory work in this area that has led to our own hypothesis that targeting CCL5 in TNBCs will have favorable therapeutic outcomes with minimal adverse impact on the general physiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available